$1.08
-0.01 (-0.92%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where COCP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 3 with posted results
Held by 4 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC) · FINRA short interest 14.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain VirusNCT07198139Incidence of norovirus-confirmed diseaseRandomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: CDI-988, Placebo · Other: Snow Mountain Virus | Norovirus | 40 | 2026-10-01 | in 43 d | 2026-02-17 |
| CDI-988 Safety Study in Healthy ParticipantsNCT05977140results2026-08-19Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: CDI-988, Placebo | Healthy Volunteers | 94 | 2025-05-23actual | — | 2026-08-19 |
| Influenza Viral Challenge Study of CC-42344 in Healthy ParticipantsNCT06160531Area under the influenza viral load-time curve (VL-AUC) of influenza challenge virusRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: CC-42344, Placebo | Influenza A | 78 | 2024-05-03actual | — | 2025-08-05 |
| CC-42344 Safety Study in Healthy ParticipantsNCT05202379results2026-02-19Part 1 SAD: Number of Participants With Treatment-Emergent Adverse Events (TEAE)Randomized · Quadruple-masked · OtherStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: CC-42344, Placebo | Influenza A | 80 | 2023-03-29actual | — | 2026-02-19 |
| Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)NCT03501550results2021-04-28Number of Subjects With Treatment Emergent Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CDI-31244, SOF/VEL | Chronic Hepatitis C | 12 | 2019-01-08actual | — | 2021-04-28 |
| A Study of CDI-31244: A Novel NNI in HV and HCV Infected SubjectsNCT02760758Number of treatment emergent adverse events (AE)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: CDI-31244, Placebo | Hepatitis C | 76 | Mar 2017actual | — | 2021-04-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19